The 75% surge in Hepion Pharmaceuticals' stock price is directly related to the anticipation of the conference call discussing the topline results from the Phase 2 ALTITUDE NASH liver function trial of Rencofilstat. Positive results from the trial could further boost the stock price, while negative results may lead to a decline. The high relevance, importance, and confidence scores are due to the direct impact of the news on the company's stock price and the potential implications of the trial results on Hepion Pharmaceuticals' future prospects.